Novo Nordisk is rated a Modest Buy with an increased price target of $80, driven by the rapid adoption of its oral Wegovy medication. Oral Wegovy has achieved over 3 million prescriptions within five months, with 80% of users being new to GLP-1 treatments, significantly expanding the addressable market. Analysts estimate that oral Wegovy could generate $12–$15 billion in annual gross profit under realistic conditions. While risks include pricing pressure, competition, and patent expirations, the current growth trajectory supports optimism for the intermediate term.
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Novo Nordisk's stock has dropped over 30% since mid-2024 amid ongoing downtrend. Investors are focusing on the upcoming Q2 earnings report, paying close attention to management's confidence in their transformation plans rather than short-term earning...
Willow Tree Research initiates coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the attractive valuation. The launch of oral Wegovy is expanding the obesity treatment market rather than just replacing injectable versions, sup...
Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like ...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
